Cargando…

The enigmatic helicase DHX9 as a candidate prognostic biomarker for resected pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, and current therapies have limited efficacy on PDAC. The DEAH-box helicase 9 (DHX9) is widely reported to influence cell biological behavior via regulating DNA replication, genomic stability, transcripti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Le-gao, Cui, Ying, Lu, Wei-qin, Wu, Hao, Jiang, Jin-song, Ding, Ke-feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791203/ https://www.ncbi.nlm.nih.gov/pubmed/36578944 http://dx.doi.org/10.3389/fonc.2022.1066717

Ejemplares similares

The enigmatic helicase DHX9 and its association with the hallmarks of cancer
por: Gulliver, Chloe, et al.
Publicado: (2020)

Prognostic Biomarkers for Pancreatic Ductal Adenocarcinoma: An Umbrella Review
por: Wang, Yizhi, et al.
Publicado: (2020)

High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma
por: Chen, Xi, et al.
Publicado: (2022)

Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma
por: Ormanns, Steffen, et al.
Publicado: (2015)

Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker
por: Song, Byeong Geun, et al.
Publicado: (2021)

Crystal structures of the DExH-box RNA helicase DHX9
por: Lee, Young-Tae, et al.
Publicado: (2023)

Potential prognostic biomarkers in pancreatic juice of resectable pancreatic ductal adenocarcinoma
por: Agrawal, Shefali
Publicado: (2017)

Digital quantitative tissue image analysis of hypoxia in resected pancreatic ductal adenocarcinomas
por: Siddiqui, Iram, et al.
Publicado: (2022)

Tumor Cell Survival Dependence on the DHX9 DExH-Box Helicase
por: Lee, Teresa, et al.
Publicado: (2016)

WRN helicase unwinds Okazaki fragment-like hybrids in a reaction stimulated by the human DHX9 helicase
por: Chakraborty, Prasun, et al.
Publicado: (2010)

Machine-learning based investigation of prognostic indicators for oncological outcome of pancreatic ductal adenocarcinoma
por: Chang, Jeremy, et al.
Publicado: (2022)

CA19.9 Serum Level Predicts Lymph-Nodes Status in Resectable Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis
por: Coppola, Alessandro, et al.
Publicado: (2021)

Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

Targeting mTOR in Pancreatic Ductal Adenocarcinoma
por: Iriana, Sentia, et al.
Publicado: (2016)

Non-coding RNAs in Pancreatic Ductal Adenocarcinoma
por: Gong, Ruining, et al.
Publicado: (2020)

DHX9 helicase promotes R-loop formation in cells with impaired RNA splicing
por: Chakraborty, Prasun, et al.
Publicado: (2018)

Dependence of p53-deficient cells on the DHX9 DExH-box helicase
por: Lee, Teresa, et al.
Publicado: (2017)

A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2020)

A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection
por: He, Chaobin, et al.
Publicado: (2019)

Development and validation of a nomogram to predict liver metastasis for pancreatic ductal adenocarcinoma after radical resection
por: Tong, Jingshu, et al.
Publicado: (2022)

Genome-Wide Profiling Reveals the Landscape of Prognostic Alternative Splicing Signatures in Pancreatic Ductal Adenocarcinoma
por: Yang, Chengkun, et al.
Publicado: (2019)

A Long Non-coding RNA Signature to Improve Prognostic Prediction of Pancreatic Ductal Adenocarcinoma
por: Zhou, Chenhao, et al.
Publicado: (2019)

Genomic Landscape in Neoplasm-Like Stroma Reveals Distinct Prognostic Subtypes of Pancreatic Ductal Adenocarcinoma
por: Jiang, Jiahong, et al.
Publicado: (2021)

Corrigendum: Serum Biomarker Panel for Diagnosis and Prognosis of Pancreatic Ductal Adenocarcinomas
por: Mehta, Shreya, et al.
Publicado: (2021)

High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma
por: Aziz, Mohammad Hosein, et al.
Publicado: (2022)

Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma
por: Hayashi, Hiromitsu, et al.
Publicado: (2021)

Pancreatic Ductal Adenocarcinoma Cortical Mechanics and Clinical Implications
por: Angstadt, Shantel, et al.
Publicado: (2022)

The immunoregulation effect of tumor microenvironment in pancreatic ductal adenocarcinoma
por: Zhang, Jingchang, et al.
Publicado: (2022)

DHX38 restricts chemoresistance by regulating the alternative pre-mRNA splicing of RELL2 in pancreatic ductal adenocarcinoma
por: Li, Zeru, et al.
Publicado: (2023)

The DNA/RNA helicase DHX9 contributes to the transcriptional program of the androgen receptor in prostate cancer
por: Chellini, Lidia, et al.
Publicado: (2022)

Identification of Novel Molecular Therapeutic Targets and Their Potential Prognostic Biomarkers Among Kinesin Superfamily of Proteins in Pancreatic Ductal Adenocarcinoma
por: Yang, Yang, et al.
Publicado: (2021)

Prognostic Value of CT Radiomic Features in Resectable Pancreatic Ductal Adenocarcinoma
por: Khalvati, Farzad, et al.
Publicado: (2019)

Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Kim, Dong Wook, et al.
Publicado: (2022)

Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma
por: Cao, Yingying, et al.
Publicado: (2022)

Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data
por: Giovinazzo, Francesco, et al.
Publicado: (2020)

A Simple Model Established by Blood Markers Predicting Overall Survival After Radical Resection of Pancreatic Ductal Adenocarcinoma
por: Zhang, Li-xiang, et al.
Publicado: (2020)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives
por: Wu, Yang, et al.
Publicado: (2021)

Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma
por: Stubbe, Benjamin Emil, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4rtsr3hctdhuainf1pe7fe5q9o